Literature DB >> 16364232

Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).

Young B Kim1, Lisa M Kopcho, Mark S Kirby, Lawrence G Hamann, Carolyn A Weigelt, William J Metzler, Jovita Marcinkeviciene.   

Abstract

Dipeptidyl peptidase-IV (DPP-IV) is a serine protease with a signature Asp-His-Ser motif at the active site. Our pH data suggest that Gly-Pro-pNA cleavage catalyzed by DPP-IV is facilitated by an ionization of a residue with a pK of 7.2 +/- 0.1. By analogy to other serine proteases this pK is suggestive of His-Asp assisted Ser addition to the P1 carbonyl carbon of the substrate to form a tetrahedral intermediate. Solvent kinetic isotope effect studies yielded a D2Okcat/Km=2.9+/-0.2 and a D2Okcat=1.7+/-0.2 suggesting that kinetically significant proton transfers contribute to rate limitation during acyl intermediate formation (leaving group release) and hydrolysis. A "burst" of product release during pre steady-state Gly-Pro-pNA cleavage indicated rate limitation in the deacylation half-reaction. Nevertheless, the amplitude of the burst exceeded the enzyme concentration significantly (approximately 15-fold), which is consistent with a branching deacylation step. All of these data allowed us to better understand DPP-IV inhibition by saxagliptin (BMS-477118). We propose a two-step inhibition mechanism wherein an initial encounter complex is followed by covalent intermediate formation. Final inhibitory complex assembly (kon) depends upon the ionization of an enzyme residue with a pK of 6.2 +/- 0.1, and we assigned it to the catalytic His-Asp pair which enhances Ser nucleophilicity for covalent addition. An ionization with a pK of 7.9 +/- 0.2 likely reflects the P2 terminal amine of the inhibitor hydrogen bonding to Glu205/Glu206 in the enzyme active site. The formation of the covalent enzyme-inhibitor complex was reversible and dissociated with a koff of (5.5 +/- 0.4) x 10(-5) s(-1), thus yielding a Ki* (as koff/kon) of 0.35 nM, which is in good agreement with the value of 0.6 nM obtained from steady-state inhibition studies. Proton NMR spectra of DPP-IV showed a downfield resonance at 16.1 ppm. Two additional peaks in the 1H NMR spectra at 17.4 and 14.1 ppm were observed upon mixing the enzyme with saxagliptin. Fractionation factors (phi) of 0.6 and 0.5 for the 17.4 and 14.1 ppm peaks, respectively, are suggestive of short strong hydrogen bonds in the enzyme-inhibitor complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364232     DOI: 10.1016/j.abb.2005.11.010

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  14 in total

Review 1.  Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Authors:  Roberta Baetta; Alberto Corsini
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

Review 3.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 4.  Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.

Authors:  Yuya Nakamura; Hitomi Hasegawa; Mayumi Tsuji; Yuko Udaka; Masatomo Mihara; Tatsuo Shimizu; Michiyasu Inoue; Yoshikazu Goto; Hiromichi Gotoh; Masahiro Inagaki; Katsuji Oguchi
Journal:  World J Diabetes       Date:  2015-06-25

Review 5.  Drug-target residence time: critical information for lead optimization.

Authors:  Hao Lu; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2010-07-19       Impact factor: 8.822

6.  Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation.

Authors:  William J Metzler; Joseph Yanchunas; Carolyn Weigelt; Kevin Kish; Herbert E Klei; Dianlin Xie; Yaqun Zhang; Martin Corbett; James K Tamura; Bin He; Lawrence G Hamann; Mark S Kirby; Jovita Marcinkeviciene
Journal:  Protein Sci       Date:  2008-02       Impact factor: 6.725

7.  New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.

Authors:  Baptist Gallwitz
Journal:  Diabetes Metab Syndr Obes       Date:  2010-05-10       Impact factor: 3.168

8.  Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes.

Authors:  Giuseppe Derosa; Pamela Maffioli
Journal:  Diabetes Metab Syndr Obes       Date:  2011-06-30       Impact factor: 3.168

9.  Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

Authors:  Aiying Wang; Charles Dorso; Lisa Kopcho; Gregory Locke; Robert Langish; Eric Harstad; Petia Shipkova; Jovita Marcinkeviciene; Lawrence Hamann; Mark S Kirby
Journal:  BMC Pharmacol       Date:  2012-04-04

10.  Hypoglycemia Associated With Drug-Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors.

Authors:  Chin-Ying Ray; Victor Chien-Chia Wu; Chun-Li Wang; Hui-Tzu Tu; Yu-Tung Huang; Chang-Fu Kuo; Shang-Hung Chang
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.